Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017

  • ID: 4413709
  • Clinical Trials
  • Region: Global
  • 1125 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Bayer AG
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • MORE
Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017

Summary

The clinical trial report, “Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017" provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the author’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Bayer AG
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Hepatocellular Carcinoma Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Hepatocellular Carcinoma
  • Sep 01, 2017: Eisai to Present 3 Abstracts on Lenvima at ESMO 2017 Congress
  • Sep 01, 2017: Eisai To Present Abstracts On Oncology Products And Pipeline At ESMO 2017 Congress
  • Sep 01, 2017: Bayer to Present Abstracts on Stivarga at ESMO 2017
  • Sep 01, 2017: Bayer to Present Data on Nexavar at ESMO 2017
  • Aug 21, 2017: Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference
  • Aug 17, 2017: Immunicum Completes Strategic Analysis and Defines Updated Clinical Development Plan for Ilixadencel
  • Aug 02, 2017: Blueprint Medicines Provides Update on Hepatocellular Carcinoma Drug BLU-554
  • Jul 19, 2017: Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma
  • Jun 29, 2017: BeiGene Presents Preliminary Phase 1 Data on BGB-A317 in Patients with Hepatocellular Carcinoma at the ESMO 19th World Congress on Gastrointestinal Cancer
  • Clinical Trial Profile Snapshots
  • Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About
  • Contact
  • Disclaimer
  • Source
List of Tables
  • Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Region, 2017*
  • Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
  • Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
  • Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2017*
  • Hepatocellular Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Hepatocellular Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2017*
  • Hepatocellular Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
  • Hepatocellular Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
  • Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2017*
  • Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
  • Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Hepatocellular Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
List of Figures
  • Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2017*
  • Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
  • Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
  • Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2017*
  • Hepatocellular Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Hepatocellular Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2017*
  • Hepatocellular Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
  • Hepatocellular Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
  • Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2017*
  • Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
  • Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Hepatocellular Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
  • Methodology
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bayer AG
  • Pfizer Inc
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Bristol-Myers Squibb Company
  • AstraZeneca Plc
  • Sanofi
  • Merck & Co Inc
  • Amgen Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll